Ann Gils Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

9/2020	Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis.
11/2019	Eczematous eruption after guselkumab treatment for psoriasis.
10/2019	Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy.
1/2019	Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases.
6/2017	The association between etanercept serum concentration and psoriasis severity is highly age-dependent.
1/2016	Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ann Gils Research Topics

Disease

36	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 06/2013
28	Crohn Disease (Crohn's Disease) 01/2021 - 02/2012
24	Ulcerative Colitis 10/2022 - 06/2013
10	Neoplasms (Cancer) 10/2021 - 08/2003
8	Cardiovascular Diseases (Cardiovascular Disease) 06/2013 - 01/2003
7	Necrosis 03/2020 - 03/2016
6	Psoriasis (Pustulosis Palmaris et Plantaris) 09/2020 - 01/2016
5	Inflammation (Inflammations) 10/2020 - 12/2005
5	Thrombosis (Thrombus) 01/2017 - 07/2002
5	Thromboembolism 02/2015 - 04/2011
4	Stroke (Strokes) 01/2016 - 04/2007
3	Ulcer 01/2020 - 01/2018
3	Ischemic Stroke 01/2016 - 04/2007
3	Atherosclerosis 01/2016 - 10/2003
2	Body Weight (Weight, Body) 01/2021 - 09/2019
2	Venous Thromboembolism 10/2020 - 11/2014
2	Rheumatoid Arthritis 01/2019 - 01/2018
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2016 - 02/2015
1	Autoimmune Diseases (Autoimmune Disease) 07/2022
1	Infections 10/2021
1	Psoriatic Arthritis 01/2019
1	Metrorrhagia (Spotting) 12/2018
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018
1	Rupture 01/2017
1	Abdominal Aortic Aneurysm 01/2017
1	Disease Progression 01/2016
1	Eczema 01/2016
1	Infarction (Infarctions) 01/2016
1	Human Influenza (Influenza) 01/2016
1	Cerebral Infarction 01/2016
1	Brain Ischemia (Cerebral Ischemia) 01/2016
1	Hemorrhage 02/2015
1	Endotoxemia 04/2012
1	Peripheral Arterial Disease 03/2011
1	Hyperlipidemias (Hyperlipidemia) 02/2006
1	Hypertension (High Blood Pressure) 11/2004

Drug/Important Bio-Agent (IBA)

36	Infliximab (Remicade)FDA Link 01/2022 - 02/2012
15	Plasminogen Activator Inhibitor 1IBA 01/2016 - 07/2002
14	AntibodiesIBA 09/2020 - 07/2011
14	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 04/2014
12	vedolizumabIBA 10/2022 - 12/2017
10	Monoclonal AntibodiesIBA 09/2020 - 04/2011
9	Adalimumab (Humira)FDA Link 07/2022 - 02/2012
7	golimumab FDA Link 01/2021 - 05/2016
6	Plasminogen Activators (Plasminogen Activator)IBA 01/2016 - 01/2003
5	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2016
5	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 01/2016 - 04/2007
5	FibrinIBA 01/2016 - 12/2005
4	VitronectinIBA 06/2013 - 06/2003
4	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 06/2013 - 03/2004
3	Immunologic Factors (Immunomodulators)IBA 10/2021 - 03/2015
3	Biosimilar PharmaceuticalsIBA 01/2020 - 01/2017
3	Ustekinumab (CNTO 1275)FDA Link 10/2019 - 01/2018
3	Peptides (Polypeptides)IBA 01/2016 - 02/2006
3	Plasminogen InactivatorsIBA 07/2014 - 06/2003
3	SerpinsIBA 07/2010 - 08/2003
2	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2021 - 01/2020
2	guselkumabIBA 09/2020 - 11/2019
2	CT-P13IBA 01/2020 - 01/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018 - 03/2016
2	IntegrinsIBA 01/2018 - 06/2016
2	Certolizumab Pegol FDA Link 01/2018 - 12/2017
2	CytokinesIBA 10/2017 - 04/2014
2	EnzymesIBA 05/2016 - 09/2015
2	ImmunosorbentsIBA 05/2016 - 09/2015
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 10/2003
2	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2016 - 02/2015
2	Fibrinogen (Factor I)FDA Link 01/2016 - 12/2005
2	Tumor Necrosis Factor InhibitorsIBA 06/2015 - 01/2015
2	Thromboplastin (Tissue Factor)IBA 02/2015 - 05/2014
2	AntigensIBA 03/2011 - 02/2006
1	SteroidsIBA 10/2022
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 10/2022
1	Neutralizing AntibodiesIBA 09/2020
1	Interleukin-23 (Interleukin 23)IBA 09/2020
1	secukinumabIBA 10/2019
1	Interleukin-12 (IL 12)IBA 07/2019
1	C-Reactive ProteinIBA 12/2018
1	Phenobarbital (Luminal)FDA Link 01/2018
1	AutoantibodiesIBA 01/2018
1	Polysaccharides (Glycans)IBA 01/2018
1	Etanercept (Enbrel)FDA Link 06/2017
1	Prostaglandins AIBA 06/2017
1	5- amino- 2- ((1- n- propyl- 1H- imidazol- 4- yl)methyl)pentanoic acidIBA 01/2017
1	Fibrinolysin FDA Link 01/2017
1	Angiotensin IIIBA 01/2017
1	neonatal Fc receptorIBA 10/2016
1	Genetic Markers (Genetic Marker)IBA 01/2016
1	NucleoproteinsIBA 01/2016
1	estropipate (Ogen)FDA LinkGeneric 01/2016
1	von Willebrand FactorIBA 01/2016
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 03/2015
1	Thrombin FDA Link 02/2015
1	ProlactinIBA 07/2014
1	Antifibrinolytic Agents (Antifibrinolytics)IBA 07/2014
1	Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA 07/2010
1	danaparoid (Orgaran)FDA Link 04/2007

Therapy/Procedure

24	Therapeutics 10/2022 - 08/2003
3	Biological Therapy 10/2019 - 09/2015
1	Colectomy 09/2016